eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2024
vol. 16
 
Share:
Send email
Share:
abstract:
Original paper

Clinical efficacy of iodine-125 radioactive particle implantation with deep hyperthermia in malignant tumor treatment: A retrospective analysis

Yuting Yuan
1
,
Yunfeng Kou
1
,
Jian Yu
2
,
Shenghe Zhang
1
,
Songbai Chen
1
,
Ruoyu Wang
3
,
Zhe Wang
3
,
Jun Zhou
1
,
Chuang Li
1

  1. Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
  2. Center of Thermotherapy, Affiliated Zhongshan Hospital of Dalian University, China
  3. Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, China
J Contemp Brachytherapy 2024; 16, 3: 202–210
DOI: https://doi.org/10.5114/jcb.2024.141407
Online publish date: 2024/06/30
View full text Get citation
 
Purpose:
In the current study, the clinical efficacy of iodine-125 (125I) radioactive particle implantation with deep hyperthermia in malignant tumor treatment was retrospectively analyzed.

Material and methods:
Sixty patients with malignant tumors treated at Zhongshan Hospital affiliated with Dalian University, from January 2021 to January 2023, were included in this retrospective analysis. Computed tomography (CT)-guided 125I radioactive particles were implanted into lesions, followed by deep hyperthermia administered for 3 days after surgery. Lesion size was evaluated monthly using CT or magnetic resonance imaging (MRI), and objective response rate (ORR) and local control rate (DCR) were calculated. Mean pain numerical score and European Organization for Research and Treatment of Cancer quality of life core scale C30 (EORTC QLQ-C30 v. 3.0) were assessed pre-treatment and post-treatment, and post-operative adverse reactions were comparatively analyzed.

Results:
After 6 months, the combined treatment resulted in a 73.33% ORR and an 81.67% DCR among 60 patients experiencing pre-treatment pain, and 49 (81.67%) exhibited effective pain relief. EORTC QLQ-C30 v. 3.0 evaluation revealed improved quality of life post-treatment. Adverse reactions during combined treatment were mitigated with targeted supportive measures, and no adverse reactions of level 2 or higher were observed.

Conclusions:
125I radioactive particle implantation with deep hyperthermia is shown to be an effective combination therapy for malignant tumors, yielding significant clinical efficacy. Notably, it enhances patient quality of life, reduces tumor burden, mitigates adverse reactions, and alleviates pain. Given its minimal trauma and mild adverse reactions, this combination therapy warrants widespread clinical application.

keywords:

malignant tumor, clinical efficacy, 125I radioactive particle implantation, deep hyperthermia

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.